Roivant and Pfizer unveil Priovant Therapeutics

Switzerland-based Roivant Sciences (Nasdaq: ROIV), which has a long history of creating new companies, has now unveiled Priovant Therapeutics, this time in collaboration with US pharma giant Pfizer (NYSE: PFE), dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality.

Priovant was established in September 2021 through a transaction between Roivant and Pfizer, in which Pfizer licensed oral and topical brepocitinib’s global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25% equity ownership interest in Priovant.

Brepocitinib is a potential first-in-class dual inhibitor of TYK2 and JAK1, a novel mechanism of action expected to potentially provide greater efficacy in multiple highly inflammatory autoimmune diseases, as compared to agents that inhibit either TYK2 or JAK1 alone. Priovant is developing oral brepocitinib as a franchise across multiple orphan and specialty autoimmune diseases with few approved therapies, high morbidity and mortality, and pathobiologies for which both TYK2 and JAK1 inhibition are expected to contribute to efficacy.